{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T09:37:09Z","timestamp":1787564229927,"version":"build-2736575974"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2010,1,13]],"date-time":"2010-01-13T00:00:00Z","timestamp":1263340800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Neuropsychopharmacol"],"published-print":{"date-parts":[[2010,4]]},"DOI":"10.1038\/npp.2009.220","type":"journal-article","created":{"date-parts":[[2010,1,13]],"date-time":"2010-01-13T10:08:07Z","timestamp":1263377287000},"page":"1155-1164","source":"Crossref","is-referenced-by-count":57,"title":["Association of the HSPG2 Gene with Neuroleptic-Induced Tardive Dyskinesia"],"prefix":"10.1038","volume":"35","author":[{"given":"Aoi","family":"Syu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroki","family":"Ishiguro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshiya","family":"Inada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasue","family":"Horiuchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Syunsuke","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maya","family":"Ishikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Makoto","family":"Arai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masanari","family":"Itokawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuhiro","family":"Niizato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuji","family":"Iritani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norio","family":"Ozaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Makoto","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akiyoshi","family":"Kakita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hitoshi","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Nawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuko","family":"Keino-Masu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eri","family":"Arikawa-Hirasawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tadao","family":"Arinami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2010,1,13]]},"reference":[{"key":"BFnpp2009220_CR1","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1016\/j.brainresbull.2004.09.001","volume":"64","author":"NP Araujo","year":"2004","unstructured":"Araujo NP, Abilio VC, Silva RH, Pereira RC, Carvalho RC, Gonzalez C et al (2004). Effects of topiramate on oral dyskinesia induced by reserpine. Brain Res Bull 64: 331\u2013337.","journal-title":"Brain Res Bull"},{"key":"BFnpp2009220_CR2","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1038\/15537","volume":"23","author":"E Arikawa-Hirasawa","year":"1999","unstructured":"Arikawa-Hirasawa E, Watanabe H, Takami H, Hassell JR, Yamada Y (1999). Perlecan is essential for cartilage and cephalic development. Nat Genet 23: 354\u2013358.","journal-title":"Nat Genet"},{"key":"BFnpp2009220_CR3","volume-title":"Diagnostic and Statistical Manual of Mental Disorders. 4th Revision","author":"AP Association","year":"1994","unstructured":"Association AP (1994). Diagnostic and Statistical Manual of Mental Disorders. 4th Revision. American Psychiatric Association: Washington DC."},{"key":"BFnpp2009220_CR4","first-page":"587","volume":"29","author":"D Ben-Shachar","year":"1993","unstructured":"Ben-Shachar D, Livne E, Spanier I, Zuk R, Youdim MB (1993). Iron modulates neuroleptic-induced effects related to the dopaminergic system. Isr J Med Sci 29: 587\u2013592.","journal-title":"Isr J Med Sci"},{"key":"BFnpp2009220_CR5","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/j.brainres.2004.10.038","volume":"1031","author":"ME Burger","year":"2005","unstructured":"Burger ME, Fachineto R, Alves A, Callegari L, Rocha JB (2005). Acute reserpine and subchronic haloperidol treatments change synaptosomal brain glutamate uptake and elicit orofacial dyskinesia in rats. Brain Res 1031: 202\u2013210.","journal-title":"Brain Res"},{"key":"BFnpp2009220_CR6","doi-asserted-by":"publisher","first-page":"772","DOI":"10.4088\/JCP.v62n1004","volume":"62","author":"SN Caroff","year":"2001","unstructured":"Caroff SN, Campbell EC, Havey J, Sullivan KA, Mann SC, Gallop R (2001). Treatment of tardive dyskinesia with donepezil: a pilot study. J Clin Psychiatry 62: 772\u2013775.","journal-title":"J Clin Psychiatry"},{"key":"BFnpp2009220_CR7","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1007\/s00406-006-0705-z","volume":"257","author":"J de Leon","year":"2007","unstructured":"de Leon J (2007). The effect of atypical versus typical antipsychotics on tardive dyskinesia: A Naturalistic Study. Eur Arch Psychiatry Clin Neurosci 257: 169\u2013172.","journal-title":"Eur Arch Psychiatry Clin Neurosci"},{"key":"BFnpp2009220_CR8","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1046\/j.1471-4159.2002.01129.x","volume":"83","author":"Y Deguchi","year":"2002","unstructured":"Deguchi Y, Okutsu H, Okura T, Yamada S, Kimura R, Yuge T et al (2002). Internalization of basic fibroblast growth factor at the mouse blood\u2013brain barrier involves perlecan, a heparan sulfate proteoglycan. J Neurochem 83: 381\u2013389.","journal-title":"J Neurochem"},{"key":"BFnpp2009220_CR9","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1111\/j.0006-341X.1999.00997.x","volume":"55","author":"B Devlin","year":"1999","unstructured":"Devlin B, Roeder K (1999). Genomic control for association studies. Biometrics 55: 997\u20131004.","journal-title":"Biometrics"},{"key":"BFnpp2009220_CR10","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1006\/tpbi.2001.1542","volume":"60","author":"B Devlin","year":"2001","unstructured":"Devlin B, Roeder K, Wasserman L (2001). Genomic control, a new approach to genetic-based association studies. Theor Popul Biol 60: 155\u2013166.","journal-title":"Theor Popul Biol"},{"key":"BFnpp2009220_CR11","doi-asserted-by":"publisher","first-page":"1349","DOI":"10.1083\/jcb.144.6.1349","volume":"144","author":"G Feng","year":"1999","unstructured":"Feng G, Krejci E, Molgo J, Cunningham JM, Massoulie J, Sanes JR (1999). Genetic analysis of collagen Q: roles in acetylcholinesterase and butyrylcholinesterase assembly and in synaptic structure and function. J Cell Biol 144: 1349\u20131360.","journal-title":"J Cell Biol"},{"key":"BFnpp2009220_CR12","doi-asserted-by":"publisher","first-page":"47","DOI":"10.3109\/10401230209147398","volume":"14","author":"J Gerlach","year":"2002","unstructured":"Gerlach J (2002). Improving outcome in schizophrenia: the potential importance of EPS and neuroleptic dysphoria. Ann Clin Psychiatry 14: 47\u201357.","journal-title":"Ann Clin Psychiatry"},{"key":"BFnpp2009220_CR13","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1111\/j.1600-0447.1988.tb05138.x","volume":"77","author":"J Gerlach","year":"1988","unstructured":"Gerlach J, Casey DE (1988). Tardive dyskinesia. Acta Psychiatr Scand 77: 369\u2013378.","journal-title":"Acta Psychiatr Scand"},{"key":"BFnpp2009220_CR14","first-page":"556","volume":"16","author":"DJ Haleem","year":"2006","unstructured":"Haleem DJ (2006). Serotonergic modulation of dopamine neurotransmission: a mechanism for enhancing therapeutics in schizophrenia. J Coll Physicians Surg Pak 16: 556\u2013562.","journal-title":"J Coll Physicians Surg Pak"},{"key":"BFnpp2009220_CR15","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1097\/FPC.0b013e3282f70492","volume":"18","author":"T Inada","year":"2008","unstructured":"Inada T, Koga M, Ishiguro H, Horiuchi Y, Syu A, Yoshio T et al (2008). Pathway-based association analysis of genome-wide screening data suggest that genes associated with the gamma-aminobutyric acid receptor signaling pathway are involved in neuroleptic-induced, treatment-resistant tardive dyskinesia. Pharmacogenet Genomics 18: 317\u2013323.","journal-title":"Pharmacogenet Genomics"},{"issue":"4","key":"BFnpp2009220_CR16","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1093\/schbul\/sbn160","volume":"36","author":"Hiroki Ishiguro","year":"2008","unstructured":"Ishiguro H, Koga M, Horiuchi Y, Noguchi E, Morikawa M, Suzuki Y et al (2008). Supportive evidence for reduced expression of GNB1L in schizophrenia. Schizophr Bull. Print copy in press (originally published online 14 November, 2008, at schizophreniabulletin.oxfordjournals.org\/cgi\/reprint\/sbn160v1).","journal-title":"Schizophrenia Bulletin"},{"key":"BFnpp2009220_CR17","doi-asserted-by":"publisher","first-page":"900","DOI":"10.1176\/ajp.137.8.900","volume":"137","author":"HL Klawans","year":"1980","unstructured":"Klawans HL, Goetz CG, Perlik S (1980). Tardive dyskinesia: review and update. Am J Psychiatry 137: 900\u2013908.","journal-title":"Am J Psychiatry"},{"key":"BFnpp2009220_CR18","doi-asserted-by":"publisher","first-page":"2483","DOI":"10.1093\/hmg\/ddp166","volume":"18","author":"M Koga","year":"2009","unstructured":"Koga M, Ishiguro H, Yazaki S, Horiuchi Y, Arai M, Niizato K et al (2009). Involvement of SMARCA2\/BRM in the SWI\/SNF chromatin-remodeling complex in schizophrenia. Hum Mol Genet 18: 2483\u20132494.","journal-title":"Hum Mol Genet"},{"key":"BFnpp2009220_CR19","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1111\/j.1471-4159.2005.03632.x","volume":"96","author":"WE Leadbeater","year":"2006","unstructured":"Leadbeater WE, Gonzalez AM, Logaras N, Berry M, Turnbull JE, Logan A (2006). Intracellular trafficking in neurones and glia of fibroblast growth factor-2, fibroblast growth factor receptor 1 and heparan sulphate proteoglycans in the injured adult rat cerebral cortex. J Neurochem 96: 1189\u20131200.","journal-title":"J Neurochem"},{"key":"BFnpp2009220_CR20","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1176\/appi.ajp.161.5.780","volume":"161","author":"AK Malhotra","year":"2004","unstructured":"Malhotra AK, Murphy Jr GM., Kennedy JL (2004). Pharmacogenetics of psychotropic drug response. Am J Psychiatry 161: 780\u2013796.","journal-title":"Am J Psychiatry"},{"key":"BFnpp2009220_CR21","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/0006-3223(91)90163-G","volume":"30","author":"MA Menza","year":"1991","unstructured":"Menza MA, Grossman N, Van Horn M, Cody R, Forman N (1991). Smoking and movement disorders in psychiatric patients. Biol Psychiatry 30: 109\u2013115.","journal-title":"Biol Psychiatry"},{"key":"BFnpp2009220_CR22","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1038\/sj.tpj.6500233","volume":"4","author":"DJ Muller","year":"2004","unstructured":"Muller DJ, Shinkai T, De Luca V, Kennedy JL (2004). Clinical implications of pharmacogenomics for tardive dyskinesia. Pharmacogenomics J 4: 77\u201387.","journal-title":"Pharmacogenomics J"},{"key":"BFnpp2009220_CR23","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1016\/S0091-3057(02)01051-1","volume":"74","author":"PS Naidu","year":"2003","unstructured":"Naidu PS, Singh A, Kaur P, Sandhir R, Kulkarni SK (2003). Possible mechanism of action in melatonin attenuation of haloperidol-induced orofacial dyskinesia. Pharmacol Biochem Behav 74: 641\u2013648.","journal-title":"Pharmacol Biochem Behav"},{"key":"BFnpp2009220_CR24","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1083\/jcb.145.4.911","volume":"145","author":"HB Peng","year":"1999","unstructured":"Peng HB, Xie H, Rossi SG, Rotundo RL (1999). Acetylcholinesterase clustering at the neuromuscular junction involves perlecan and dystroglycan. J Cell Biol 145: 911\u2013921.","journal-title":"J Cell Biol"},{"key":"BFnpp2009220_CR25","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1016\/S0896-6273(01)00584-0","volume":"33","author":"AL Perrier","year":"2002","unstructured":"Perrier AL, Massoulie J, Krejci E (2002). PRiMA: the membrane anchor of acetylcholinesterase in the brain. Neuron 33: 275\u2013285.","journal-title":"Neuron"},{"key":"BFnpp2009220_CR26","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1097\/YCO.0b013e328017f6b1","volume":"20","author":"G Remington","year":"2007","unstructured":"Remington G (2007). Tardive dyskinesia: eliminated, forgotten, or overshadowed? Curr Opin Psychiatry 20: 131\u2013137.","journal-title":"Curr Opin Psychiatry"},{"key":"BFnpp2009220_CR27","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1016\/S0028-3908(99)00031-3","volume":"38","author":"MA Riva","year":"1999","unstructured":"Riva MA, Molteni R, Tascedda F, Massironi A, Racagni G (1999). Selective modulation of fibroblast growth factor-2 expression in the rat brain by the atypical antipsychotic clozapine. Neuropharmacology 38: 1075\u20131082.","journal-title":"Neuropharmacology"},{"key":"BFnpp2009220_CR28","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.cbi.2005.10.007","volume":"157\u2013158","author":"RL Rotundo","year":"2005","unstructured":"Rotundo RL, Rossi SG, Kimbell LM, Ruiz C, Marrero E (2005). Targeting acetylcholinesterase to the neuromuscular synapse. Chem Biol Interact 157\u2013158: 15\u201321.","journal-title":"Chem Biol Interact"},{"key":"BFnpp2009220_CR29","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1080\/j.1440-1614.2000.00737.x","volume":"34","author":"PS Sachdev","year":"2000","unstructured":"Sachdev PS (2000). The current status of tardive dyskinesia. Aust N Z J Psychiatry 34: 355\u2013369.","journal-title":"Aust N Z J Psychiatry"},{"key":"BFnpp2009220_CR30","first-page":"189","volume":"40","author":"T Saito","year":"1986","unstructured":"Saito T, Ishizawa H, Tsuchiya F, Ozawa H, Takahata N (1986). Neurochemical findings in the cerebrospinal fluid of schizophrenic patients with tardive dyskinesia and neuroleptic-induced parkinsonism. Jpn J Psychiatry Neurol 40: 189\u2013194.","journal-title":"Jpn J Psychiatry Neurol"},{"key":"BFnpp2009220_CR31","first-page":"486","volume":"39","author":"NR Schooler","year":"1982","unstructured":"Schooler NR, Kane JM (1982). Research diagnoses for tardive dyskinesia. Arch Gen Psychiatry 39: 486\u2013487.","journal-title":"Arch Gen Psychiatry"},{"key":"BFnpp2009220_CR32","first-page":"CD000207","volume":"3","author":"IA Tammenmaa","year":"2002","unstructured":"Tammenmaa IA, McGrath JJ, Sailas E, Soares-Weiser K (2002). Cholinergic medication for neuroleptic-induced tardive dyskinesia. Cochrane Database Syst Rev 3: CD000207.","journal-title":"Cochrane Database Syst Rev"},{"key":"BFnpp2009220_CR33","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1016\/j.pnpbp.2004.05.045","volume":"28","author":"IA Tammenmaa","year":"2004","unstructured":"Tammenmaa IA, Sailas E, McGrath JJ, Soares-Weiser K, Wahlbeck K (2004). Systematic review of cholinergic drugs for neuroleptic-induced tardive dyskinesia: a meta-analysis of randomized controlled trials. Prog Neuropsychopharmacol Biol Psychiatry 28: 1099\u20131107.","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"BFnpp2009220_CR34","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1002\/mds.20823","volume":"21","author":"D Tarsy","year":"2006","unstructured":"Tarsy D, Baldessarini RJ (2006). Epidemiology of tardive dyskinesia: is risk declining with modern antipsychotics? Mov Disord 21: 589\u2013598.","journal-title":"Mov Disord"},{"key":"BFnpp2009220_CR35","doi-asserted-by":"publisher","first-page":"10079","DOI":"10.1074\/jbc.271.17.10079","volume":"271","author":"JM Whitelock","year":"1996","unstructured":"Whitelock JM, Murdoch AD, Iozzo RV, Underwood PA (1996). The degradation of human endothelial cell-derived perlecan and release of bound basic fibroblast growth factor by stromelysin, collagenase, plasmin, and heparanases. J Biol Chem 271: 10079\u201310086.","journal-title":"J Biol Chem"}],"container-title":["Neuropsychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/npp2009220.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/npp2009220","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/npp2009220.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T20:20:29Z","timestamp":1684441229000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/npp2009220"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,1,13]]},"references-count":35,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2010,4]]}},"alternative-id":["BFnpp2009220"],"URL":"https:\/\/doi.org\/10.1038\/npp.2009.220","relation":{},"ISSN":["0893-133X","1740-634X"],"issn-type":[{"value":"0893-133X","type":"print"},{"value":"1740-634X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,1,13]]}}}